Matt DeNardo
speaker
183 appearances
1 recordings
1 series
first heard Jul 2026
last heard 11 Jul
Matt DeNardo’s voice in public audio — every appearance, attributed to the second.
Trend
recordings per month · last 12 monthsRecordings per month over the last 12 months — 1 in all, peaking in Jul 2026 with 1.
Appearances
And one of the things that helped us learn as we conducted user research and understood the user needs of our clinical and patient population more is that there were really unmet needs in patients with the disorders of consciousness for neural monitoring.
So disorders of consciousness covers a wide range of disorders that include coma, but can transition all the way up to a minimally conscious state where the patient is not deeply unconscious.
And one of the challenges that we saw with the current standard of care.
in that patient population is that it's really governed by clinical observation and almost like a survey where the clinicians are observing patients and interacting with them and describing how, and scoring, I should say, how the patients respond to those interactions.
So there's a rubric that clinicians carry out
And they carry this out, you know, episodically when they have to be physically present and they have to be able to interact with the patient to do this.
And one of the challenges that we saw is that because of this episodic nature and that it requires a clinician's time is that you're getting a very small snapshots of this patient's actual state.
And our thinking is like we can do better by applying neuromonitoring through our brain computer interface for these patients where we can basically monitor them 24-7 and understand how changes in their brain activity can map into how they are really doing as patients with a disorder of consciousness.
And I think our vision for how we can take that forward is initially to start with kind of a neuromonitoring application, but then to kind of grow and say, all right, what else can we do with this now that we have this information?
And so that's kind of the trajectory that Axsoft is on is to be able to address that.
these needs of patients and disorders of consciousness who might have had a stroke or traumatic brain injury to get into the place where they are now and to learn more about their neural signal and what we can do with that information once we have it.
And I think that's really the direction that XSoft is going over the next few years is to be able to get
This technology developed to the point where it can be a marketed medical device that can start to serve patients with this particular need and in a way that both relieves the burden on the clinician from carrying out these episodic monitoring tasks and provides a more complete picture of how these patients are actually performing.
So I think having a CRO that truly functions as a part of your team is probably the most important thing to being able to work with a clinical site anywhere.
And
I think it is worth spending the time to make sure your CRO is familiar with your use case, familiar with your clinical needs.
If you have clinical advisors to be able to have them talk to your CRO directly and explain clinician to clinician kind of level of explanation of what it is that you're trying to achieve and why first in human is the appropriate next step if it's a first in human study that you're conducting.
And I think building that relationship first helps everything downstream go easier because we've already then answered the fundamental questions about what it is and why we're doing that.
And that helps align the entire team towards answering questions that haven't yet been asked.
I think that's the most important bit in order to maintain a timeline is
Showing 161–180 of 183 · page 9 of 10
← Previous
Next →